Key result
DNA aptamer PAN-2 inhibits PA endonuclease and cross-protects against multiple influenza strains at ~10 nM.
Effect estimate: IC50 ~10 nM
DNA aptamers targeting the PAN domain of influenza A virus demonstrate cross-protective antiviral efficacy in vitro, suggesting potential as anti-influenza agents.
May enable aptamer-based anti-influenza strategies targeting conserved PAN; leaves open in vivo efficacy and clinical translation.
Amino acid residues in the N-terminal of the PA subunit (PAN) of the influenza A virus polymerase play critical roles in endonuclease activity, protein stability, and viral RNA (vRNA) promoter binding. In addition, PAN is highly conserved among different subtypes of influenza virus, which suggests PAN to be a desired target in the development of anti-influenza agents. We selected DNA aptamers targeting the intact PA protein or the PAN domain of an H5N1 virus strain using systematic evolution of ligands by exponential enrichment (SELEX). The binding affinities of selected aptamers were measured, followed by an evaluation of in vitro endonuclease inhibitory activity. Next, the antiviral effects of enriched aptamers against influenza A virus infections were examined. A total of three aptamers targeting PA and six aptamers targeting PAN were selected. Our data demonstrated that all three PA-selected aptamers neither inhibited endonuclease activity nor exhibited antiviral efficacy, whereas four of the six PAN-selected aptamers inhibited both endonuclease activity and H5N1 virus infection. Among the four effective aptamers, one exhibited cross-protection against infections of H1N1, H5N1, H7N7, and H7N9 influenza viruses, with a 50% inhibitory concentration (IC50) of around 10 nM. Notably, this aptamer was identified at the 5th round but disappeared after the 10th round of selection, suggesting that the identification and evaluation of aptamers at early rounds of selection may be highly helpful for screening effective aptamers. Overall, our study provides novel insights for screening and developing effective aptamers for use as anti-influenza drugs.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2015) studied Influenza A virus infection. DNA aptamer PAN-2 vs. Mock treatment / aptamer library control was evaluated on Inhibition of influenza virus replication (IC50 ~10 nM). The DNA aptamer PAN-2 inhibited the endonuclease activity of the PA subunit and exhibited cross-protection against infections of H1N1, H5N1, H7N7, and H7N9 influenza viruses with an IC50 of approximately 10 nM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: